---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-129343"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-20T23:52:17.321252+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit upholds Collegium's Belbuca patents; blocks Alvogen generic until 2032

## Summary
- Alvogen conceded infringement; Federal Circuit ruling bars generic entry until 2032 patent expiry (9,901,539 patent).
- Court upheld validity of claims in '866 (2027) and '539 (2032) patents; remanded some claims of '866 and '843 patents (2027) for reconsideration.
- Decision reinforces strength of Belbuca patent portfolio, protecting key chronic pain product from generic competition.

## SEC filing metadata
- accession: 0001104659-22-129343
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465922129343/0001104659-22-129343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465922129343/tm2233280d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-129343
- JSON: https://secwatch.observer/filing/0001104659-22-129343.json
- Plain text: https://secwatch.observer/filing/0001104659-22-129343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.